Skip to content

Author

C. Exertier

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Second Generation of 2,2'-Di(indol-3-yl)ethanamines as Antileishmanial Agents: Phenotypic Hit Identification and Pharmacophore Studies.

The urgent need for new antileishmanial drugs persists due to resistance and toxicity associated with current treatments. Although bisindoles represent a promising chemotype, our first-generation 2,2'-di(indol-3-yl)ethanamines, inspired by a natural marine alkaloid, displayed significant cytotoxicity despite potent act...

Gian Marco Elisi, Antonio Gkoutzamanis, S. Maestrini et al. · 0 citations
Open access Sep 2026

UbC4 from Leishmania is a Druggable E2 Ubiquitin Conjugating Enzyme: Structural Basis and Fragment Hits for Future E2-Recruiting PROTAC Development

Leishmaniasis is a neglected disease that affects around two million people every year. Current treatments are often highly toxic or prone to resistance, underscoring the urgent need for new therapeutic strategies. PROTACs may offer a promising alternative, as they can potentially mitigate both toxicity and resistance....

C. Exertier, Lorenzo Antonelli, A. Liuzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.